Laidlaw lowered the firm’s price target on Beyond Air (XAIR) to $5 from $8 and keeps a Buy rating on the shares following the fiscal Q2 report. The firm says Beyond Air is at the early execution stage of LungFit PH commercialization by the new commercial team. It expects more significant sales starting in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
Questions or Comments about the article? Write to editor@tipranks.com